Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesRecordati

Recordati

PortfolioPortfolio WatchlistWatchlist
Company price
None GBX 0.00(0%)
Last update at 2026-10-28T03:28:35.279226Z
Market Cap
9810.06M

Momentum Score

…

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing's syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing's syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
43.78
Low
54.61
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
53.00
Dividend Yield
3.08%
Revenue TTM
2618.38M
Revenue Per Share
12.74
Gross Profit TTM
1854.45M
Debt / Equity
0.61
ROE
23.37%
Net Debt
-
ROCE
25.13%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax - - 455.66M 444.14M 417.94M
Net income - - 354.98M 368.82M 312.38M
Selling general administrative - - 421.86M 445.59M 401.22M
Gross profit - - 1042.04M 1044.95M 956.67M
Ebit 536.00M 504.55M 475.49M 471.01M 444.64M
Operating income - - 469.02M 465.27M 442.22M
Other operating expenses 8.10M 0.65M 1.71M 1.61M 0.84M
Interest expense - 0.00M 0.00M 0.00M 0.00M
Tax provision - - 100.63M 75.28M 105.51M
Interest income - - 13.20M 20.62M 17.98M
Income tax expense 89.10M 77.38M 100.63M 75.28M 105.51M
Total revenue - - 1448.87M 1481.85M 1352.23M
Cost of revenue - - 406.83M 436.90M 395.57M
Net income applicable to common shares 312.30M 385.97M 354.98M 368.82M 312.38M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets - - 2711.65M 2808.93M 2161.26M
Intangible assets - - 1115.81M 1161.76M 672.11M
Other current assets - 26.46M 19.61M 20.21M 11.61M
Total liab - - 1435.67M 1610.35M 1197.87M
Total stockholder equity - - 1275.98M 1198.58M 963.39M
Other current liab - 129.35M 113.47M 190.76M 124.84M
Common stock - 26.14M 26.14M 26.14M 26.14M
Retained earnings 1728.66M 1557.80M 1402.89M 1274.97M 1118.61M
Other liab 187.28M 47.69M 78.69M 86.02M 66.29M
Good will - - 562.12M 577.97M 577.79M
Other assets - 163.61M 130.38M 351.50M 132.05M
Cash - - 13.00M 46.54M 25.61M
Total current liabilities - 626.42M 578.46M 586.75M 490.74M
Short term debt - - 12.57M 13.39M 16.91M
Short long term debt total - - 778.24M 937.34M 640.65M
Other stockholder equity - -159.05M -149.25M -92.77M -119.46M
Property plant equipment - 131.12M 133.25M 133.34M 88.83M
Total current assets - 850.10M 772.95M 809.35M 699.93M
Net tangible assets -746.92M -255.62M -353.51M -277.60M -256.29M
Net receivables - 350.33M 313.86M 374.33M 284.20M
Long term debt - - 760.59M 937.34M 640.65M
Inventory 424.08M 228.73M 251.25M 226.88M 206.08M
Accounts payable - 177.93M 132.10M 175.48M 165.02M
Treasury stock - - -87.52M -93.48M -145.61M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - - - - 0.07M
Change to liabilities - - 0.00M 46.34M -38.61M
Total cashflows from investing activities - - - -87.50M -131.56M
Net borrowings - - - -79.89M -39.40M
Total cash from financing activities - - 341.28M -355.94M -264.29M
Net income 416.50M 389.20M 312.30M 385.97M 354.98M
Change in cash - - - 56.35M 0.31M
Total cash from operating activities - - - 491.65M 403.57M
Depreciation - - - 97.58M 93.67M
Other cashflows from investing activities - - - - 0.12M
Dividends paid - - - 216.74M 212.72M
Change to inventory - - - 17.51M -42.92M
Change to account receivables - - - -43.79M 6.03M
Sale purchase of stock - - - - -12.17M
Other cashflows from financing activities - - - - 1.74M
Change to netincome - - - -11.96M 30.42M
Capital expenditures 0.00M 0.00M 23.89M 21.85M 21.26M
Change in working capital - - - - -170.10M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

Recordati

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing's syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing's syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.

Via Matteo Civitali,1, Milan, MI, Italy, 20148

39 02 487871

https://recordati.com

4614

Name Title Year Born
Dr. Robert Koremans M.D. CEO & Director 1962
Ms. Cathrin Petty Exec. Director 1973
Mr. Giampiero Mazza Exec. Director 1969
Mr. Giorgio De Palma Exec. Director 1974
Mr. Luigi Felice La Corte Group CFO & Exec. Director 1969
Ms. Federica De Medici Director of Investor Relations & Corp. Communications NA
Ms. Daria Ghidoni Group Gen. Counsel NA
Mr. Giovanni Minora Group Audit & Compliance NA
Mr. Gabriele Finzi Exec. VP of Corp. Devel. & Licensing NA
Mr. Giuseppe Gualazzini Sr. VP of Group HR 1959

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…